APP
LTRN icon

Avantax Planning Partners’s Lantern Pharma LTRN Stock Holding History

Avantax Planning Partners’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,640
Closed -$42.7K – 447
2024
Q3 		$42.7K Hold
11,640
– – ﹤0.01% 434
2024
Q2 		$54.4K Hold
11,640
– – ﹤0.01% 458
2024
Q1 		$102K Buy
+11,640
New +$62.2K ﹤0.01% 454

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Avantax Planning Partners's LTRN Position: Q4 2024 in Review

Avantax Planning Partners sold out of Lantern Pharma (LTRN) in Q4 2024, closing a stake of 11,640 shares — an estimated $42.7K sold.

Avantax Planning Partners first reported a position in LTRN in Q1 2024 and held it in 3 quarters. The position peaked at $102K in Q1 2024. 32 funds tracked by Wall St. Rank hold LTRN as of Q4 2024.

  • Avantax Planning Partners reported no remaining Lantern Pharma position as of Q4 2024 after selling out during the quarter.
  • Avantax Planning Partners sold 11,640 Lantern Pharma shares in Q4 2024, an estimated $42.7K.
  • Avantax Planning Partners first reported a position in Lantern Pharma in Q1 2024 and held it in 3 quarters.
  • Avantax Planning Partners's Lantern Pharma position peaked at $102K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2024.

Based on Avantax Planning Partners's 13F filing for Q4 2024, filed 7 Feb 2025.